AEON Biopharma, Inc. (NASDAQ:AEON - Free Report) - Investment analysts at HC Wainwright raised their Q2 2024 EPS estimates for AEON Biopharma in a research note issued on Wednesday, May 15th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.19) per share for the quarter, up from their previous forecast of ($0.31). HC Wainwright has a "Buy" rating and a $6.00 price target on the stock. HC Wainwright also issued estimates for AEON Biopharma's Q3 2024 earnings at ($0.22) EPS, Q4 2024 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.87) EPS, FY2026 earnings at ($0.88) EPS and FY2027 earnings at ($0.54) EPS.
AEON Biopharma (NASDAQ:AEON - Get Free Report) last posted its quarterly earnings data on Friday, March 29th. The company reported ($0.71) earnings per share for the quarter.
AEON Biopharma Stock Performance
Shares of NASDAQ AEON traded up $0.17 during mid-day trading on Monday, hitting $1.70. 136,267 shares of the stock were exchanged, compared to its average volume of 70,195. The stock's fifty day simple moving average is $6.98 and its two-hundred day simple moving average is $7.34. AEON Biopharma has a twelve month low of $1.38 and a twelve month high of $17.17.
Hedge Funds Weigh In On AEON Biopharma
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Atalaya Capital Management LP bought a new position in shares of AEON Biopharma during the third quarter worth $19,827,000. Formidable Asset Management LLC bought a new position in shares of AEON Biopharma in the 3rd quarter valued at about $360,000. Finally, Vanguard Group Inc. grew its position in shares of AEON Biopharma by 261.8% in the 1st quarter. Vanguard Group Inc. now owns 758,992 shares of the company's stock valued at $8,804,000 after acquiring an additional 549,207 shares during the period. 22.78% of the stock is owned by institutional investors.
About AEON Biopharma
(
Get Free Report)
AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.
Recommended Stories
Before you consider AEON Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AEON Biopharma wasn't on the list.
While AEON Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
